05Jun 2025
Tarlatamab Improves Survival Over Chemotherapy in Relapsed Small-Cell Lung Cancer, Phase 3 Trial Finds

Tarlatamab Improves Survival Over Chemotherapy in Relapsed Small-Cell Lung Cancer, Phase 3 Trial Finds

A phase 3 trial shows that tarlatamab significantly improves overall survival compared to chemotherapy in patients with small-cell lung cancer who progressed after platinum-based therapy. Tarlatamab also showed better progression-free survival, fewer severe adverse events, and improved symptom control.

  • #family health

Like

Save

Share